The increase in metabolism could potentially represent an elevation in energy expenditure that pairs well with the effects of an incretin agonist to reduce food intake. However, pharmacologically targeting the glucagon receptor remains a controversial strategy
The involvement of GLP-1 in PD can be simplified to the activation of the MAPK/extracellular signal-regulated kinase 1/2 (ERK) pathway, which has an important role in synaptic plasticity, and the PI3K/Akt pathway signaled by GLP-1 receptor stimulation and the subsequent increase in cAMP and PKA and PI3K activation [73]
Because tesamorelin and retatrutide act on different receptor systems, no formal pharmacokinetic interaction studies have been conducted
Dose conversion considerations There is no perfect dose equivalence between different GLP-1 medications because they work through different receptor combinations and have different potencies
semaglutide Choosing the right medication is a personal decision you should make with the guidance of your healthcare provider
The PKA and EPAC2 pathways are triggered by both receptors'activation of adenylate cyclase, which raises intracellular cAMP and causes insulin synthesis and release, cellular proliferation, and antiapoptotic effects
